RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have cancers like folli…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Engineered immune cells show promise in battling tough lymphoma after transplant
Disease control OngoingThis early-phase trial tests a new approach for people with high-risk B-cell non-Hodgkin lymphoma that has come back after initial treatment. Participants receive a stem cell transplant followed by an infusion of their own genetically modified immune cells designed to target and …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control OngoingThis study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Engineered immune cells target tough lymphoma after transplant
Disease control OngoingThis early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goals are to check safety and find the best …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 05, 2026 12:10 UTC